NCT05595590View on ClinicalTrials.gov

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 20, 2022

Primary Completion Date

October 19, 2024

Study Completion Date

October 19, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Tislelizumab

Administered as an intravenous (IV) infusion 200mg every 3 weeks (Q3W)

RADIATION

Pulse radiation

66-70Gy/33-35Fx, 2Gy/Fx.

Trial Locations (2)

Unknown

RECRUITING

Sichuan Cancer Hosiptal, Chengdu

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER